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ABSTRACT We compare the folding equilibrium of the globular domain of the human prion protein with two variants of this
domain, for which an additional disulﬁde bond was introduced into the location where it is found in the naturally occurring doppel
protein. We ﬁnd that the unfolding transition midpoint of the variants is shifted toward higher denaturant concentration, indicating
that the engineered disulﬁde bond signiﬁcantly stabilizes the global protein structure. Our results further reveal that the two-
disulﬁde variant proteins, while possessing the same global fold as the wild-type, display marked differences in their folding
pathway—in particular, the absence of a characteristica-helix tob-sheet transition, which is a fundamental feature associatedwith
misfolding of proteins into amyloid ﬁbrils, especially in the context of prion diseases. These surprising characteristics of disulﬁde
mutant prion proteins have important implications for the understanding of the generic aberrant processes leading to amyloid ﬁbril
formation and protein aggregation, as well as providing insight into possible therapeutic strategies.
INTRODUCTION
Prions are the infectious agents responsible for a group of
fatal neurodegenerative diseases, including Creutzfeldt-Jakob
disease in humans, which are characterized by the conver-
sion of cellular prion protein (PrPC) into the pathological
scrapie form (PrPSc). Soluble recombinant prion proteins
from various mammalian species have been shown to consist
of two distinct domains: a 100-residue N-terminal tail of
residues 23–120, which is ﬂexibly disordered in large parts,
and a well-structured C-terminal globular domain of residues
121–230 that is rich in a-helix secondary structure and
contains a small antiparallel b-sheet and a single disulﬁde
bond Cys179–Cys214 (1–5). A two-disulﬁde variant hPrP
(M166C/E221C) of this globular domain of the human prion
protein hPrP (121–230) with an additional disulﬁde bond
linking residues Cys166 and Cys221 has recently been pre-
pared as a recombinant protein (6), where the design of the
novel proteins was based on the location of the additional
disulﬁde bond in the naturally occurring PrP-like Doppel
protein (7) (Fig. 1 b). The nuclear magnetic resonance
(NMR) structure of hPrP(M166C/E221C) (6) shows that this
variant possesses the same global fold as wild-type
hPrP(121–230) (Fig. 1), with the engineered additional
disulﬁde bond being accommodated with slight, strictly
localized conformational changes. High compatibility of hPrP
structure with insertion of a second disulﬁde bridge between
helix a3 and the loop connecting helix a2 and the second
b-strand (Fig. 1) was further evidenced by expression and
spectroscopic characterization of the variant protein
hPrP(M166C/Y225C) and model calculations with addi-
tional variant structures (6).
Here, we have studied the pH dependence of guanidinium
chloride (GdmCl) and temperature-induced unfolding of
hPrP(M166C/E221C) and hPrP(M166C/Y225C) monitored
with circular dichroism (CD) and compare the results to pre-
viously published structural and thermodynamic data of
human and mouse prion proteins. Our measurements show
that the variant proteins not only display a signiﬁcantly
enhanced stability but alsomarked differences in their folding
pathway, in particular the absence of a b-sheet rich folding
intermediate which is a characteristic of the mammalian prion
proteins (8,9), and is thought to be involved in the patholog-
ical pathways leading to misfolding and aggregation of PrPSc
in prion diseases.
METHODS
Protein production
The two variant proteins hPrP(M166C/E221C) and hPrP (M166C/Y225C)
were expressed as inclusion bodies in Escherichia coli and puriﬁed by high-
afﬁnity column refolding (10), resulting in similar yield as for wild-type
hPrP(121–230) (6). The formation of an additional disulﬁde bond was
conﬁrmed by mass spectrometry and NMR spectroscopy. The 1H NMR
spectra of both proteins showed that the preparations are homogeneous.
Spectroscopic characterization
Circular dichroism spectra were recorded with a JASCO J720 spectropolar-
imeter interfaced with a Peltier-type temperature control unit, with 1 mm or
0.2 mm pathlength cuvette. The ellipticity at 222 nmwas used for monitoring
GdmCl-induced unfolding. Measurements were performed at pH 7 in buffer
containing 20mM sodium phosphate and at pH 5 in buffer containing 20mM
sodium acetate.
Congo Red spectroscopic assay
A solution of Congo Red was freshly dissolved at 7 mg/mL in PBS buffer
(5 mM potassium phosphate, 150 mM NaCl, pH 7.4) and ﬁltered through a
0.2-mm syringe ﬁlter. Absorptions spectra were recorded using a Tecan Saﬁre
Multi-DetectionMonochrometerMicroplate Reader (Tecan, Sta¨fa, Switzerland)
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between 400 and 700 nm at room temperature using volumes of 200 ml. First
the spectrometer was zeroed using only the buffer solution. Then 1 ml of the
Congo Red stock solution was added to 199 ml of the buffer and the
spectrum recorded to serve as a control. Solutions of the prion proteins were
prepared at a concentration of 1 mg/ml in buffer containing 20 mM sodium
phosphate at pH 7 and in buffer containing 20 mM sodium acetate and 1 M
GdnHCl at pH 5. Subsequently 20 ml of the protein solution was added to
179 ml of PBS buffer and 1 ml of Congo Red solution, and the spectrum was
measured after 10 min of incubation. Additionally, as a positive control,
hPrPb(23–230)(Alicon PrP-beta, Alicon, Schlieren, Switzerland) was used.
Mathematical modeling and ﬁtting
Denaturation curves were ﬁtted to a two-state model, assuming that the free
energy DG of unfolding is linearly dependent upon the concentration of
denaturant [D] present in the solution (11,12): DG ¼ DG01 m[D], where m
is the cooperativity of unfolding and DG0 is DG in the absence of denaturant.
Evaluation of the equilibrium constants in the transition region was obtained
by extrapolation of the pre- and post-transitional baselines into the transition
region. The two-state model used to ﬁt the data assumes the dependence of
the observed signal, Sobs, as
Sobs ¼
ðS0N1mN½DÞexp 
DG
01m½D
RT
 
1 S0D1mD½D
11 exp DG
01m½D
RT
  ;
where S0N and S
0
D are the intercepts; mN and mD are the slopes of the pre- and
post-transition regimes, respectively; T is the absolute temperature in
Kelvin; and R is the ideal gas constant. In particular, the transition midpoint
[D]1/2 can be determined from the condition that the argument in the
exponentials vanishes, yielding [D]1/2 ¼ DG0/m.
Thermally induced unfolding
Protein concentration was 24 mM in 10 mM sodium acetate at pH 4.5.
Thermal denaturation experiments were performed by monitoring the
circular dichroism at 222 nm, while changing the temperature from 10C to
90C with a constant rate of change of 50C per hour. The unfolding
experiments were performed twice, and very similar results were obtained.
RESULTS
Stabilization of globular protein structure
The globular protein stability of wild-type hPrP(121–230)
and the variant proteins were measured by monitoring the
molar ellipticity at 222 nm in solutions containing different
concentrations of GdmCl. At pH 7.0, hPrP(121–230)
undergoes a highly cooperative two-state transition (Fig. 2
a) with a midpoint of transition [D]1/2 ¼ 2.1 M and a free
energy of unfolding in the absence of denaturant DG0 ¼ –19
kJ mol1. These thermodynamic values are nearly identical
FIGURE 2 GdmCl-dependent mean residue molar ellipticity of human
prion proteins. (a) In buffer containing 20 mM sodium phosphate at pH 7.0.
(b) In buffer containing 20 mM sodium acetate at pH 5.0. The spectra in
panels a and b were recorded with 30 mM protein solutions at 22C: solid
squares, wild-type hPrP(121–230); open squares, hPrP(M166C/Y225C);
and solid circles, hPrP(M166C/E221C).
FIGURE 1 (a) Ribbon-drawing of the three-dimensional structure of
hPrP(M166C/E221C) (6). The engineered additional disulﬁde bond Cys-
166–Cys-221 is indicated with an asterisk. The ﬁgure was prepared with the
programMOLMOL (31). In panel b, sequence alignment of the human prion
protein segment 165–230 and the human doppel protein segment 93–153,
showing the natural disulﬁde bonds (shaded lines) and location of the
additional disulﬁde bond (solid line) for the hPrP(M166C/Y225C) and
(M166C-E221C)mutants, which is inspired from the corresponding location in
the naturally occurring doppel. The residues which were changed are in bold.
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to those determined for the prion protein construct hPrP(90–
231) (8). A single folding transition was also observed for
the two hPrP(121–230) disulﬁde variant proteins (Fig. 2 a).
However, hPrP(M166C/E221C) and hPrP(M166C/Y225C)
showed an increase in the transition midpoint [D]1/2, indi-
cating that the global structures are stabilized by the engineered
disulﬁde bonds (13,14). The lower folding cooperativity of
the variant proteins indicates a deviation from a two-state
folding mechanism.
Absence of b-sheet rich folding intermediate in
the folding pathway of disulﬁde mutant prions
At pH 5.0, wild-type hPrP(121–230) shows two distinctive
folding transition regions with transition midpoints at 1.3 and
2.7 M GdmCl, clearly indicating the presence of a folding
intermediate that is maximally populated at ;2 M GdmCl
(Fig. 2 b). The existence of a stable folding intermediate dur-
ing equilibrium unfolding in GdmCl has also been reported
for hPrP(90–231) (8).
Although the two cysteine variant proteins are soluble up to
1mMprotein concentration in the absence of denaturant, their
decreased solubility at low GdmCl concentration precluded
quantitative CD measurements (Fig. 2 b) so that we were not
able to determine the folding transition model for these pro-
teins. Similar to the data obtained at neutral pH, the observed
folding transition midpoints of hPrP(M166C/E221C) and
hPrP(M166C/Y225C) are shifted toward higher molarities of
denaturant with respect to the second transition midpoint of
hPrP(121–230), and the folding cooperativity is decreased
(Fig. 2 b).
To gain insight into the conformational properties of the
human prion proteins under conditions corresponding to the
presence of the stable folding intermediate of wild-type
hPrP(121–230), we measured far-UV CD spectra at pH 5.0
in the presence and absence of 2 M GdmCl. The spectra of
the three proteins in the absence of denaturant are essentially
similar (Fig. 3), with the minima at 208 and 222 nm indi-
cating a largely a-helical structure (5,6). The slight differ-
ences in the spectra of the variant proteins relative to the
wild-type can be understood as a consequence of the addi-
tional absorption from the second disulﬁde-bond in the far-
UV region (15), since the structures are very similar apart
from small localized changes around the disulﬁde bridge
insertion points (6). Furthermore, it is known from NMR
chemical shift measurements that the population of a-helical
secondary structure within helix a3 of both hPrP(M166C/
E221C) and hPrP(M166C/Y225C) is slightly decreased (6).
At 2 M GdmCl, where the folding intermediate of wild-
type hPrP(121–230) ismaximally populated, the doublemini-
mum in the CD spectrum of hPrP(121–230) is replaced by a
single minimum at 213 nm (Fig. 3 a), which is characteristic
of proteins rich in b-sheet secondary structure. A similar
monomeric folding intermediate has been described at pH
4.0 for hPrP(90–231), which is maximally populated at 1 M
GdmCl (8), and also for mouse PrP(121–231) at 4 M urea
(9). It has been postulated that these intermediates—which
remarkably are absent in our disulﬁde variant proteins as
discussed below—may represent a soluble precursor of PrPSc.
Such models are consistent with the current understanding of
the generic events associated with amyloid ﬁbril formation,
which involve partially unfolded structures that ﬁrst revers-
ibly form preﬁbrillar b-sheet rich species and then ﬁnally
assemble to form the mature amyloid ﬁbrils (16). Recent
FIGURE 3 Circular dichroism spectra of human prion proteins. (a) Wild-
type hPrP(121–230); (b) hPrP(M166C/E221C); and (c) hPrP(M166C/
Y225C). The spectra were recorded with 20 mM protein solutions in 20
mM sodium acetate at pH 5.0 and 22C, either in the presence (bold line) or
in the absence (thin line) of 2 M GdmCl.
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evidence (17) suggests, however, that multiple pathways
exist for the misfolding of hPrP(91–231) (17), and only some
intermediates are likely to be involved in vivo in the
processes that, starting from normal soluble prion proteins,
produce pathological aggregates, thus explaining the com-
plexity of producing infectious prions in vitro.
On the other hand, the CD spectra of the two variant prion
proteins in 2 M GdmCl remain typical for a protein rich in
a-helix structure (Fig. 3, b and c), indicating that there is
no accumulation of a folding intermediate with increased
b-sheet structure. The relative increase in amplitude at 208
nm versus 222 nm, when compared with the native protein,
may be rationalized by a partial transition of a-helix into a
random coil conformation, but there is no evidence for an
a-helix-to-b-sheet transition in the presence of GdmCl, as is
the case for wild-type protein. Thus, the introduction of a
second disulﬁde bond into the globular prion protein domain
not only results in increased overall protein stability, but also
introduces novel features into folding pathways of the
proteins, which otherwise have the same native fold.
Finally, inspired by the elegant experiments of Baskskov
et al. (17) and considering that the disulﬁde mutant proteins
showed evidence of reduced solubility in the region cor-
responding to 0 M , [GdmCl] , 2 M, we examined by
using Congo Red binding assays whether there were signs of
amyloid ﬁbril formation under these conditions. This is
especially relevant at pH 5, where the wild-type protein is
folding into the intermediate maximally populated at 2 M
GdmCl, which has a predominantly b-sheet character, a
feature which appears to be shared among many mammalian
prions constructs (8,9), and places the conﬁrmation closer
structurally to that acquired in amyloid ﬁbrils. The absor-
bance spectrum of Congo Red displays a characteristic red-
shift when the dye is bound to amyloid (18); which speciﬁc
effect is thought to be due to the interaction of the planar
molecule with the cross-b core structure in amyloid ﬁbrils.
We found, as shown in Fig. 4, that the absorption spectrum
of both mutants under these conditions did not show any
signiﬁcant shift, suggesting that any aggregation in this
regime is of an amorphous nature and not composed of
amyloid ﬁbrils. On the other hand, suspended aggregates of
amyloid ﬁbrils that formed from hPrPb(23–230) (19) under
these conditions display the characteristic red-shift in the
absorption, which spectroscopically conﬁrms their ﬁbrillar
nature (Fig. 4).
Increase in thermal stability of the
protein structure
To reﬁne our understanding of the fundamental differences
in the folding of the disulﬁde mutant prion proteins, the ef-
fects of elevated temperature were investigated. The thermal
unfolding of the three prion proteins under acidic conditions
occurs in a single transition (Fig. 5), but, as for GdmCl-
induced unfolding previously discussed, the qualitatively
different equilibrium unfolding characteristics of wild-type
versus variant proteins induced is also manifested. The two-
state thermal unfolding of hPrP(121–230) is highly cooper-
ative with a melting temperature of ;60C (Fig. 5 a). The
folding transition of hPrP(M166C/Y225C) and hPrP(M166C/
E221C) is much less cooperative, and is shifted by .10C
toward higher temperatures (Fig. 5, b and c), reﬂecting again
the greater stability. The exact temperature of the folding
transition could not be determined for the variant proteins,
because even at 100C they have not reached the post-
unfolding regime and contain a signiﬁcant degree of protein
secondary structure with negative ellipticity at 222 nm.
DISCUSSION
A generic feature of prion diseases is the misfolding of
soluble prion protein into amyloid ﬁbrils and other higher
order aggregates. This process is likely to be the key to
FIGURE 4 Congo Red binding assays of human prion proteins. Absorp-
tions spectrum (a) at pH 5 in 1M GdmCl for hPrP(M166C/E221C) (black
dashed line), hPrP(M166C/Y225C) (solid line), hPrP(121–230) (shaded
line), and hPrPb(23–230) (shaded dashed line). Only hPrPb(23–230) shows
the characteristic red-shift of the absorptions maxima from 480 nm to 500 nm
and the development of a shoulder at 540 nm (18), which indicate the
presence of amyloid ﬁbrils. For comparison (b), in data at pH 7 0M GdmCl
is shown, where similar observations hold.
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understanding both the evolution and the transmissibility of
such disease states, which implies that the characterization of
the folding pathways of prion proteins is essential for develop-
ingmodels of, and eventually therapies against, these pathogenic
events (17).
We introduced an additional disulﬁde bond into the
globular domain of the prion protein at the analog location
where it is found in the doppel protein (20), which has two
disulﬁde bridges (Fig. 1 b), and found that this inﬂuenced
dramatically the folding pathway of the protein, despite
leaving the native structure of the protein nearly untouched.
The stability of the native state was greatly enhanced, and the
characteristic a-to-b transition was removed from the
folding pathway. It is interesting to compare these results
with the equivalent measurements for the doppel protein:
Whyte et al. (20) studied both the wild-type doppel protein
and a certain mutant where the disulﬁde bridge, correspond-
ing to the location where it is found in the prion proteins, was
kept but the second one was removed—exactly the comple-
ment of this work. It was found that removing the disulﬁde
bond destabilized the native structure of the doppel protein,
in agreement with our present conclusion that making the
prion protein more doppel-like increased its stability. How-
ever, it was found that even for the prionlike doppel protein
with only one disulﬁde bond, the unfolding was a two-state
process, with no evidence of the a-to-b transition charac-
teristic of the prion proteins. This implies that the presence of
this intermediate in the unfolding process of prion proteins
depends on the sequence differences between the doppel and
the prion proteins and even though our doppel-like prion
proteins lose this feature, it cannot be restored in prionlike
doppel proteins by the simple deletion of the corresponding
disulﬁde bond (20).
We ﬁnally wish to discuss some implications for ideas
with regard to therapeutic aspects. Currently there are no
drugs available for the treatment of prion diseases in humans
and animals (21,22). Within the framework of the protein-
only hypothesis (23), at least two mechanisms can be imag-
ined that could prevent the accumulation of toxic misfolded
protein conformations resulting in TSE. The ﬁrst mechanism
relies on a PrPC-binder that speciﬁcally binds to the normal
form of the prion protein, thus preventing PrPC from folding
into PrPSc. The second mechanism would use a PrPSc-binder
to either block the homophilic assembly of PrPSc into
amyloid ﬁbrils or to interfere with a heterophilic interaction
with other macromolecules that otherwise are implicated in
pathogenic pathways. The advantage of PrPSc-binders over
PrPC-binders is that they do not interfere with the yet
unknown physiological function of the cellular form of the
protein. Only a few compounds with therapeutic potential,
including a monoclonal PrPSc-binding antibody (24) and a
13-residue b-sheet breaker peptide (25), have been identiﬁed
which speciﬁcally bind to the scrapie conformation of prion
proteins. Another strategy in this direction that has been
suggested for TSE treatment is based on the design of soluble
PrP derivatives that bind to PrPSc, but cannot be converted
by a template-assisted mechanism and thus inactivate the
bound PrPSc molecule. Bu¨rkle and co-workers have shown
that the presence of amino acids 114–121 of mouse PrP plays
an important role in the conversion of PrPC into PrPSc and
that a deletion mutant lacking these residues behaves as a
dominant negative mutant with respect to PrPSc accumula-
tion in cell culture (26). Recently, Aguzzi and co-workers
constructed a soluble dimeric prion protein that binds PrPSc
in vivo and antagonizes prion disease (27). Dominant neg-
ative inhibition could thus form a basis for treatment or pre-
vention of prion diseases.
The combination of earlier structural data (6) and the
present thermodynamical data on hPrP(M166C/E221C) and
hPrP(M166C/Y225C) suggests that disulﬁde variants of PrP
may also be applicable as a dominant negative treatment for
prion diseases. Clearly, the data presented in this work show
that these novel proteins stabilized by an additional disulﬁde
bond are either denatured or in a PrPC-like conformation.
This feature makes them good candidates as inhibitors of
PrPSc formation assuming a heteroduplex-model for PrP
conversion (28), i.e., a model involving a transient complex
between PrPC and PrPSc. In fact, recombinant two-disulﬁde
PrPC might be used to demonstrate the existence of a
heterodimeric complex with native PrPSc. The preservation
of the native three-dimensional structure in the PrP variants
(6) makes it likely that these have a similar afﬁnity to PrPSc
as does wild-type PrPC. The PrPSc-binding site of PrPC is not
known, but there is evidence from genetic experiments (29,
30) that the region of helix a1 (residues 144–154 in human
PrP) and the preceding loop region (residues 132–143 in
human PrP) are involved in PrPSc binding. This region is
structurally unchanged after introduction of an additional
disulﬁde bond between helix a3 and the loop connecting
helix a2 and the second b-strand (6). The increased
FIGURE 5 Temperature-dependent mean residue molar ellipticity of
human prion proteins. (a) Wild-type hPrP(121–230); (b) hPrP(M166C/
Y225C); and (c) hPrP(M166C/E221C).
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[D]1/2-values in Fig. 2 and melting temperatures in Fig. 4 of
the variant proteins indicate that a higher amount of free
energy is required for transforming PrPSc-bound two-disulﬁde
PrPC into a conformation that is competent for folding into
PrPSc. Therefore, the additional disulﬁde bonds in the variant
proteins should, per se, decrease efﬁciency of prion propaga-
tion and thus delay progression of prion disease. At acidic pH,
the protection against a conversion into a pathogenic protein
conformation presumably may be even more pronounced,
because the a-helix secondary structure of the variant pro-
teins resists a conformational transition into b-sheet second-
ary structure, as shown in Fig. 3, b and c. Thus, within the
environment of endosomes or lysosomes, PrPSc would
probably become trapped in an inactive complex with a
bound PrPC disulﬁde variant that is unable to promote prion
propagation.
It will be of interest to investigate if such a mechanism of
blocking the growth of PrPSc ﬁbrils by forming a stable
heterodimeric complex can be established during future cell
culture and animal experiments, where the recombinant
disulﬁde variant prion proteins could be intraperitoneally
inoculated or may be even expressed in vivo using a gene
therapeutic approach.
In conclusion, we have shown how, without modifying the
native fold of the human prion protein, it is possible to signiﬁ-
cantly enhance its structural stability, and change the folding
pathway such that potentially amyloidogenic intermediates
are not present. These ﬁndings shed light on possible general
therapeutic concepts and strategies for the treatment of a
variety of neurodegenerative diseases.
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